Markets Edge — Capital flows, CMO moves, M&A

ISABELLA'S ISLAY M&A Intelligence May 5, 11:02 AM EDT

American Express Global Business Travel

Long Lake acquires Amex GBT for $6.3B in take-private deal

Long Lake has agreed to acquire American Express Global Business Travel, the world's largest corporate travel platform, for $6.3 billion, with strategic backing from General Catalyst and Alpha Wave.

ReadingCorporate travel consolidation is entering the buyout phase. Operators without scale have 18 months before the second round of price compression.

WatchThe next three acquisitions in travel management will be announced at lower entry multiples. Within 90 days.

Read full analysis → Original ↗

m&atravelprivate equitycorporate

HENRI IV Capital Markets May 5, 11:02 AM EDT

Ares Management

Bloomberg ↗

Ares launches lower-leverage private credit fund with tighter discipline

Ares Management is planning a new private credit fund with significantly lower leverage and more disciplined underwriting standards, signaling a shift toward more conservative deployment in the current credit cycle.

ReadingPrivate credit returns will compress. Managers pricing on leverage spreads will face LP redemptions. Discipline is now table stakes.

WatchOther $50B+ managers will announce similar fund structures within 60 days. The spread compression comes after.

Read full analysis → Original ↗

private creditcapital marketsleveragediscipline

MACALLAN 1926 Venture Intelligence May 5, 11:02 AM EDT

Odyssey Therapeutics

Renaissance Capital ↗

Odyssey Therapeutics prices IPO at $225M for autoimmune therapies

Odyssey Therapeutics, a biotech focused on autoimmune disease treatments, has set pricing terms for a $225 million IPO, expected to close this week.

ReadingBiotech IPO access remains tight. Clinical validation is the price of admission. Early-stage companies without Phase 2 data should expect 18-month runway extensions.

WatchTwo more biotech IPOs price within 14 days. The third one reprices lower.

Read full analysis → Original ↗

biotechipoautoimmuneventure

LOUIS XIII Healthcare Intelligence May 5, 11:02 AM EDT

Mobia Medical

Renaissance Capital ↗

Mobia Medical prices nerve stimulation IPO at $150M this week

Mobia Medical, a nerve stimulation device manufacturer, has set terms for a $150 million IPO, pricing this week.

ReadingMedtech IPO windows are narrow and selective. Device makers with regulatory approvals find liquidity. The experimental ones wait.

WatchThe next three medtech IPOs price within 21 days. Two of them will be larger than Mobia.

Read full analysis → Original ↗

medtechipohealthcaredevices

PAPPY 23 Venture Intelligence May 5, 11:02 AM EDT

Audax Private Debt

Pulse 2.0 / Alternatives Watch ↗

Audax closes $1B continuation fund led by Pantheon Ventures

Audax Private Debt has closed a $1 billion continuation vehicle led by Pantheon, consolidating existing private credit positions into a new fund structure.

ReadingContinuation funds confirm credit portfolio lock-up into 2027. New commitments to private credit vehicles should model extended hold periods.

WatchTwo more $750M+ continuation funds close within 45 days. All in credit or infrastructure.

Read full analysis → Original ↗

private creditcontinuation fundventureaudax

JOHNNIE BLUE Capital Markets May 5, 11:02 AM EDT

Private Credit Market

Reuters ↗

US borrowers shift from private credit to syndicated loans as costs narrow

Borrowers are increasingly moving away from expensive private credit structures toward bank-led syndicated loans as cost gaps narrow between the two financing options.

ReadingPrivate credit fund targets will miss. The sweet spot for new deployments is $50M-$250M tickets where bank syndication is friction. Larger deals move back to public markets.

WatchThree private credit managers announce LP distribution plans within 60 days. The repricing comes quietly.

Read full analysis → Original ↗

private creditsyndicated loansborrower behaviorrates

WELL POUR M&A Intelligence May 5, 11:02 AM EDT

Nice Systems

CTech ↗

Five bidders advance in Nice's $2.5B Actimize sale process

Nice Systems has narrowed the bidding for its Actimize compliance software unit to five qualified buyers, signaling progress in a competitive $2.5 billion sale process.

ReadingCompliance software remains attractive to strategic and PE buyers. Final pricing will reflect competitive tension, not strategic desperation. Expect $2.2B-$2.4B close.

WatchThe winner is announced within 45 days. The losers' next targets emerge 30 days after that.

Read full analysis → Original ↗

m&anice systemscompliancesoftware